HER2 is not only overexpressed in 20-30% of breast cancer, but also found in lung cancer, liver cancer, ovarian cancer and other cancers (19–23), and can be used as targets for targeted cancer treatment of most malignant cancers. This evidence concerns the gene ERBB2 and breast carcinoma.